Does the media refer more to RAPP or PTCT?

In the previous week, PTC Therapeutics had 14 more articles in the media than Rapport Therapeutics. MarketBeat recorded 19 mentions for PTC Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.69 beat PTC Therapeutics' score of 0.47 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, COGT or RAPP?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A

Is COGT or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Rapport Therapeutics N/A -24.78% -23.44%

Does the media refer more to COGT or RAPP?

In the previous week, Rapport Therapeutics had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Rapport Therapeutics and 3 mentions for Cogent Biosciences. Rapport Therapeutics' average media sentiment score of 1.69 beat Cogent Biosciences' score of 1.20 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, SRRK or RAPP?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A

Is SRRK or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Rapport Therapeutics N/A -24.78% -23.44%

Does the media favor SRRK or RAPP?

In the previous week, Scholar Rock had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Scholar Rock and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.69 beat Scholar Rock's score of 1.14 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RAPP or LNTH?

In the previous week, Rapport Therapeutics and Rapport Therapeutics both had 5 articles in the media. Rapport Therapeutics' average media sentiment score of 1.69 beat Lantheus' score of 0.84 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, RAPP or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is RAPP or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -24.78% -23.44% Belite Bio N/A -13.14% -12.88%

Does the media favor RAPP or BLTE?

In the previous week, Rapport Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Rapport Therapeutics and 4 mentions for Belite Bio. Rapport Therapeutics' average media sentiment score of 1.69 beat Belite Bio's score of 0.56 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Rapport Therapeutics (RAPP) Competitors

$41.46 +0.87 (+2.14%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$41.79 +0.33 (+0.80%)

As of 05:23 AM Eastern

Compare

RAPP vs. PTCT, COGT, SRRK, LNTH, and BLTE

Should you buy Rapport Therapeutics stock or one of its competitors? MarketBeat compares Rapport Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rapport Therapeutics include PTC Therapeutics (PTCT), Cogent Biosciences (COGT), Scholar Rock (SRRK), Lantheus (LNTH), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Rapport Therapeutics compare to PTC Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Rapport Therapeutics presently has a consensus price target of $57.86, suggesting a potential upside of 39.55%. PTC Therapeutics has a consensus price target of $91.57, suggesting a potential upside of 17.31%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rapport Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Rapport Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Rapport Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

Rapport Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Rapport Therapeutics' return on equity of -24.78% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, PTC Therapeutics had 14 more articles in the media than Rapport Therapeutics. MarketBeat recorded 19 mentions for PTC Therapeutics and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.69 beat PTC Therapeutics' score of 0.47 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rapport Therapeutics and PTC Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Rapport Therapeutics' return on equity of -24.78% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Rapport Therapeutics	N/A	-24.78%	-23.44%

In the previous week, Rapport Therapeutics had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Rapport Therapeutics and 3 mentions for Cogent Biosciences. Rapport Therapeutics' average media sentiment score of 1.69 beat Cogent Biosciences' score of 1.20 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cogent Biosciences is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 13.55%. Rapport Therapeutics has a consensus price target of $57.86, indicating a potential upside of 39.55%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Summary

Rapport Therapeutics beats Cogent Biosciences on 9 of the 11 factors compared between the two stocks.

How does Rapport Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Rapport Therapeutics' return on equity of -24.78% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Rapport Therapeutics	N/A	-24.78%	-23.44%

In the previous week, Scholar Rock had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Scholar Rock and 5 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.69 beat Scholar Rock's score of 1.14 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 4.13%. Rapport Therapeutics has a consensus target price of $57.86, indicating a potential upside of 39.55%. Given Rapport Therapeutics' higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Rapport Therapeutics beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Lantheus?

Rapport Therapeutics (NASDAQ:RAPP) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Lantheus has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Lantheus	$1.55B	4.31	$233.56M	$4.15	24.67

Rapport Therapeutics currently has a consensus target price of $57.86, suggesting a potential upside of 39.55%. Lantheus has a consensus target price of $108.29, suggesting a potential upside of 5.78%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Rapport Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Rapport Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

In the previous week, Rapport Therapeutics and Rapport Therapeutics both had 5 articles in the media. Rapport Therapeutics' average media sentiment score of 1.69 beat Lantheus' score of 0.84 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Rapport Therapeutics' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Lantheus	18.05%	29.32%	15.00%

99.1% of Lantheus shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lantheus beats Rapport Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rapport Therapeutics compare to Belite Bio?

Rapport Therapeutics (NASDAQ:RAPP) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Rapport Therapeutics presently has a consensus price target of $57.86, suggesting a potential upside of 39.55%. Belite Bio has a consensus price target of $203.00, suggesting a potential upside of 38.40%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Rapport Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Rapport Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

In the previous week, Rapport Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Rapport Therapeutics and 4 mentions for Belite Bio. Rapport Therapeutics' average media sentiment score of 1.69 beat Belite Bio's score of 0.56 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio's return on equity of -13.14% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Belite Bio	N/A	-13.14%	-12.88%

0.5% of Belite Bio shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Belite Bio is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

Rapport Therapeutics beats Belite Bio on 8 of the 14 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.94B	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-15.95	20.98	27.01	24.38
Price / Sales	N/A	311.10	519.43	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	4.08	8.54	10.80	6.33
Net Income	-$111.48M	$23.83M	$3.59B	$331.02M
7 Day Performance	-1.26%	-2.77%	-1.47%	-0.33%
1 Month Performance	8.36%	5.85%	2.78%	-1.29%
1 Year Performance	188.32%	52.15%	28.50%	21.30%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	3.0914 of 5 stars	$41.46 +2.1%	$57.86 +39.5%	+183.4%	$1.94B	N/A	N/A	N/A	Positive News
PTCT PTC Therapeutics	3.3362 of 5 stars	$89.20 +4.4%	$91.57 +2.7%	+57.8%	$7.40B	$1.73B	N/A	1,410	Insider Trade
COGT Cogent Biosciences	1.8489 of 5 stars	$40.01 +1.4%	$43.73 +9.3%	+247.2%	$6.84B	N/A	N/A	80	Positive News
SRRK Scholar Rock	1.9611 of 5 stars	$56.56 +2.2%	$56.00 -1.0%	+39.4%	$6.78B	N/A	N/A	140
LNTH Lantheus	3.0348 of 5 stars	$103.41 +0.6%	$101.86 -1.5%	+23.2%	$6.73B	$1.54B	24.92	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. PTCT, COGT, SRRK, LNTH, and BLTE

How does Rapport Therapeutics compare to PTC Therapeutics?

Summary

How does Rapport Therapeutics compare to Cogent Biosciences?

Summary

How does Rapport Therapeutics compare to Scholar Rock?

Summary

How does Rapport Therapeutics compare to Lantheus?

Summary

How does Rapport Therapeutics compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. PTCT, COGT, SRRK, LNTH, and BLTE

How does Rapport Therapeutics compare to PTC Therapeutics?

Do analysts rate RAPP or PTCT?

Which has more volatility and risk, RAPP or PTCT?

Which has stronger earnings & valuation, RAPP or PTCT?

Is RAPP or PTCT more profitable?

Does the media refer more to RAPP or PTCT?

Summary

How does Rapport Therapeutics compare to Cogent Biosciences?

Is COGT or RAPP more profitable?

Does the media refer more to COGT or RAPP?

Which has stronger valuation and earnings, COGT or RAPP?

Do analysts rate COGT or RAPP?

Which has more risk & volatility, COGT or RAPP?

Summary

How does Rapport Therapeutics compare to Scholar Rock?

Which has better earnings & valuation, SRRK or RAPP?

Which has more risk and volatility, SRRK or RAPP?

Is SRRK or RAPP more profitable?

Does the media favor SRRK or RAPP?

Do analysts rate SRRK or RAPP?

Do institutionals and insiders hold more shares of SRRK or RAPP?

Summary

How does Rapport Therapeutics compare to Lantheus?

Which has preferable valuation & earnings, RAPP or LNTH?

Do analysts recommend RAPP or LNTH?

Which has more risk and volatility, RAPP or LNTH?

Does the media refer more to RAPP or LNTH?

Is RAPP or LNTH more profitable?

Do insiders and institutionals have more ownership in RAPP or LNTH?

Summary

How does Rapport Therapeutics compare to Belite Bio?

Do analysts recommend RAPP or BLTE?

Which has more risk and volatility, RAPP or BLTE?

Does the media favor RAPP or BLTE?

Is RAPP or BLTE more profitable?

Do insiders and institutionals hold more shares of RAPP or BLTE?

Which has stronger valuation & earnings, RAPP or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools